Manuela Valente Sells 2,597 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Manuela Valente sold 2,597 shares of SOPHiA GENETICS stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $4.85, for a total transaction of $12,595.45. Following the sale, the insider directly owned 221,651 shares in the company, valued at $1,075,007.35. The trade was a 1.16% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Manuela Valente also recently made the following trade(s):

• On Tuesday, April 7th, Manuela Valente sold 2,376 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.87, for a total transaction of $11,571.12.
• On Thursday, March 19th, Manuela Valente sold 380 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.79, for a total transaction of $1,820.20.

SOPHiA GENETICS Trading Down 0.3%

Shares of SOPH traded down $0.01 during trading hours on Wednesday, reaching $4.89. 64,929 shares of the company traded hands, compared to its average volume of 188,371. The company’s fifty day moving average price is $4.78 and its two-hundred day moving average price is $4.68. The company has a market capitalization of $334.64 million, a price-to-earnings ratio of -9.58 and a beta of 1.04. The company has a quick ratio of 1.84, a current ratio of 1.96 and a debt-to-equity ratio of 1.01. SOPHiA GENETICS SA has a 12 month low of $2.58 and a 12 month high of $5.70.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.08). The company had revenue of $21.71 million for the quarter, compared to the consensus estimate of $21.20 million. SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. Equities research analysts predict that SOPHiA GENETICS SA will post -0.96 earnings per share for the current fiscal year.

Institutional Investors Weigh In On SOPHiA GENETICS

Several hedge funds have recently bought and sold shares of SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in SOPHiA GENETICS by 246.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after acquiring an additional 5,432,871 shares in the last quarter. Akre Capital Management LLC boosted its stake in SOPHiA GENETICS by 66.2% during the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after acquiring an additional 1,481,636 shares in the last quarter. Alta Wealth Advisors LLC bought a new stake in SOPHiA GENETICS during the third quarter worth about $6,708,000. Royce & Associates LP bought a new stake in SOPHiA GENETICS during the fourth quarter worth about $2,009,000. Finally, 1492 Capital Management LLC bought a new stake in SOPHiA GENETICS during the fourth quarter worth about $973,000. Institutional investors own 31.59% of the company’s stock.

Wall Street Analysts Forecast Growth

SOPH has been the topic of a number of research reports. BTIG Research reaffirmed a “buy” rating and set a $7.00 target price on shares of SOPHiA GENETICS in a research note on Tuesday, March 3rd. Guggenheim lifted their target price on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, SOPHiA GENETICS presently has an average rating of “Hold” and a consensus target price of $7.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.